BTI
RPRX icon

Blue Trust Inc’s Royalty Pharma RPRX Stock Holding History

Blue Trust Inc’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.9K Sell
640
-49
-7% -$2.55K ﹤0.01% 1481
2026
Q1 		$33.1K Buy
689
+437
+173% +$19.1K ﹤0.01% 1483
2025
Q4 		$9.74K Buy
252
+166
+193% +$6.33K ﹤0.01% 1868
2025
Q3 		$3.04K Buy
86
+34
+65% +$1.23K ﹤0.01% 2081
2025
Q2 		$1.87K Sell
52
-157
-75% -$5.2K ﹤0.01% 2135
2025
Q1 		$6.51K Buy
209
+52
+33% +$1.65K ﹤0.01% 2054
2024
Q4 		$4K Sell
157
-1,046
-87% -$27.7K ﹤0.01% 2123
2024
Q3 		$31.7K Buy
1,203
+943
+363% +$26.1K ﹤0.01% 1759
2024
Q2 		$7.9K Buy
260
+247
+1,900% +$6.85K ﹤0.01% 2021
2024
Q1 		$395 Sell
13
-63
-83% -$1.86K ﹤0.01% 2029
2023
Q4 		$2K Buy
+76
New +$2.09K ﹤0.01% 2204
2023
Q3 		– Sell
-23
Closed -$1K – 2254
2023
Q2 		$1K Sell
23
-31
-57% -$1.05K ﹤0.01% 1914
2023
Q1 		$2K Sell
54
-7
-11% -$260 ﹤0.01% 2043
2022
Q4 		$2K Hold
61
– – ﹤0.01% 1956
2022
Q3 		$3K Hold
61
– – ﹤0.01% 1714
2022
Q2 		$2K Buy
+61
New +$2.5K ﹤0.01% 1691

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Blue Trust Inc's RPRX Position: Q2 2026 in Review

Blue Trust Inc reduced its Royalty Pharma (RPRX) stake by 7.1% in Q2 2026, selling an estimated $2.55K and leaving 640 shares worth $35.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1481.

Blue Trust Inc first reported a position in RPRX in Q2 2022 and has held it in 16 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Blue Trust Inc held 640 shares of Royalty Pharma worth $35.9K as of Q2 2026.
  • Blue Trust Inc sold 49 Royalty Pharma shares in Q2 2026, an estimated $2.55K.
  • Royalty Pharma made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #1481 holding.
  • Blue Trust Inc first reported a position in Royalty Pharma in Q2 2022 and has held it in 16 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.